CANDEL THERAPEUTICS, INC. Earnings Per Share (Basic)
CANDEL THERAPEUTICS, INC. (CADL) reported Earnings Per Share (Basic) of -$0.52 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.52.
- CANDEL THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.14, a 193.33% decline year-over-year.
- CANDEL THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.54.
- CANDEL THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.21.
- CANDEL THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$0.72.
- CANDEL THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$1.74.
- CANDEL THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$1.31.
- CANDEL THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$0.65.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.52 10-Q · filed 2026-08-13 | -$0.70 10-Q · filed 2026-08-13 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.44 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2026-03-31 | -$0.14 10-Q · filed 2026-05-14 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.86 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.97 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-12-31 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.72 10-K · filed 2026-03-12 |
| 2025-09-30 | -$0.21 10-Q · filed 2025-11-13 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.17 10-Q · filed 2025-11-13 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-06-30 | -$0.09 10-Q · filed 2026-08-13 | $0.05 10-Q · filed 2026-08-13 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-03-31 | $0.15 10-Q · filed 2026-05-14 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-05-14 |
| 2024-12-31 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.74 10-K · filed 2026-03-12 |
| 2024-09-30 | -$0.33 10-Q · filed 2025-11-13 | -$1.06 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$1.35 10-Q · filed 2025-11-13 | -$1.74 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2024-06-30 | -$0.74 10-Q · filed 2025-08-14 | -$1.03 10-Q · filed 2025-08-14 | -$1.42 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$1.71 derived: net income ÷ weighted average shares · filed 2025-08-14 |
| 2024-03-31 | -$0.28 10-Q · filed 2025-05-13 | -$0.66 derived: net income ÷ weighted average shares · filed 2025-05-13 | -$0.96 derived: net income ÷ weighted average shares · filed 2025-05-13 | -$1.29 derived: net income ÷ weighted average shares · filed 2025-05-13 |
| 2023-12-31 | -$0.38 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$0.67 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$1.01 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$1.31 10-K · filed 2025-03-13 |
| 2023-09-30 | -$0.29 10-Q · filed 2024-11-14 | -$0.62 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$0.93 10-Q · filed 2024-11-14 | -$1.10 derived: net income ÷ weighted average shares · filed 2024-11-14 |
| 2023-06-30 | -$0.33 10-Q · filed 2024-08-13 | -$0.64 10-Q · filed 2024-08-13 | -$0.81 derived: net income ÷ weighted average shares · filed 2024-08-13 | -$1.11 derived: net income ÷ weighted average shares · filed 2024-08-13 |
| 2023-03-31 | -$0.30 10-Q · filed 2024-05-14 | -$0.48 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$0.78 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$0.93 derived: net income ÷ weighted average shares · filed 2024-05-14 |
| 2022-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$0.48 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$0.62 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$0.65 10-K · filed 2024-03-28 |
| 2022-09-30 | -$0.30 10-Q · filed 2023-11-09 | -$0.44 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.48 10-Q · filed 2023-11-09 | -$0.42 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-06-30 | -$0.14 10-Q · filed 2023-08-10 | -$0.17 10-Q · filed 2023-08-10 | -$0.12 derived: net income ÷ weighted average shares · filed 2023-08-10 | -$0.72 derived: net income ÷ weighted average shares · filed 2023-08-10 |
| 2022-03-31 | -$0.03 10-Q · filed 2023-05-11 | $0.03 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$0.57 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$1.41 derived: net income ÷ weighted average shares · filed 2023-05-11 |
| 2021-12-31 | $0.06 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$0.56 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$1.49 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$1.91 10-K · filed 2023-03-30 |
| 2021-09-30 | -$0.69 10-Q · filed 2022-11-10 | -$1.90 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$2.42 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$1.46 10-Q · filed 2022-08-05 | -$1.85 10-Q · filed 2022-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |